WELCOME

The TauRx group of life science companies is focused on the development of novel treatments and diagnostics for Alzheimer's Disease (AD) and other neurodegenerative diseases.

Our team includes highly skilled and internationally recognized pharmaceutical experts in many aspects of drug development. From initial discovery through to clinical trials, data analysis and product registration, we are working together towards halting the progression of Alzheimer's, frontotemporal dementia (FTD) and other neurodegenerative diseases.

Our Protein Aggregation Inhibitors target the underlying pathology of dementia, with the aim of modifying or halting disease progression and an ultimate goal of prevention. Our lead compound, LMTX™, targets aggregation of tau, synuclein, TDP-43 and huntingtin protein. Its primary development in Alzheimer's is focused in its activity as a Tau Aggregation Inhibitor (TAI).

TauRx is headquartered in Singapore with research and development activities in Aberdeen, Scotland.

January 2015:First Evidence of…

The Journal of Alzheimer’s Disease has published today the results of the first clinical trial of a Tau…

September 2014:TauRx Therapeutics…

TauRx Therapeutics Ltd has achieved its target enrolment of 700 subjects with mild Alzheimer’s disease…

August 2014:TauRx: In the News

A list of recent articles that have featured TauRx

July 2014:TauRx Therapeutics…

TauRx Therapeutics Ltd today announced it has achieved its target enrolment of 833 subjects into one…

March 2014:TauRx Chairman to…

Prof. Wischik, Chairman of TauRx Therapeutics, will present a scientific update at the 13th International…

First Evidence of Potential Efficacy of Tau Aggregation Inhibitor Therapy in Alzheimer’s Disease

TauRx Completes Recruitment to Phase 3 Alzheimer’s Disease Studies

Science Home Block

Pioneering Science: Understanding Tau Pathology in Neurodegenerative Diseases

The Tau-hypothesis of Alzheimer’s disease pathogenesis proposes that age-related malfunctions in the cellular processing of Tau protein, which is a normal component of healthy cells, leads to Tau protein misfolding and loss of neuronal function, then to the formation of neurotoxic aggregates and ultimately disease symptoms. See Science for more.

Patients Caregivers Home Block

For Patients and Caregivers

We are currently conducting Phase 3 clinical trials in both Alzheimer's Disease and Frontotemporal Dementia (FTD).  If you'd like to learn more please see our Patients & Caregivers section.

Research Development Home Block

Alzheimer’s Innovation: In Our Hands

By 2050, nearly 104 million people [one third of the current U.S. population] are predicted to have Alzheimer’s disease, according to the World Health Organisation. This underscores the need for new treatments to halt and prevent the formation of Tau tangles - the hallmark sign of dementia.  See FTD Rationale